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Abstract
HIV-1 Tat protein is an important pathogenic factor in HIV-1-associated neurological diseases.
One hallmark of HIV-1 infection of the central nervous system (CNS) is astrocytosis, which is
characterized by elevated GFAP expression in astrocytes. We have shown that Tat activates GFAP
expression in astrocytes (Zhou, et al., Mol. Cell. Neurosci. 27:296, 2004) and that GFAP is an
important regulator of Tat neurotoxicity (Zou, et. al., Am. J. Pathol. 171:1293, 2007). However,
the underlying mechanisms for Tat-mediated GFAP up-regulation are not understood. In the
current study, we reported concurrent up-regulation of adenovirus E1a-associated 300 kDa protein
p300 and GFAP in Tat-expressing human astroytoma cells and primary astrocytes. We showed
that p300 was indeed induced by Tat expression and HIV-1 infection and that the induction
occurred at the transcriptional level through the cis-acting elements of early growth response 1
(Egr-1) within its promoter. Using siRNA, we further showed that p300 regulated both
constitutive and Tat-mediated GFAP expression. Moreover, we showed that ectopic expression of
p300 potentiated Tat transactivation activity and increased proliferation of HIV-1-infected
astrocytes, but had little effect on HIV-1 replication in these cells. Taken together, these results
demonstrate for the first time that Tat is a positive regulator of p300 expression, which in turn
regulates GFAP expression, and suggest that the Tat-Egr-1-p300-GFAP axis likely contributes to
Tat neurotoxicity and predisposes astrocytes to be an HIV-1 sanctuary in the CNS.
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INTRODUCTION
HIV-1 infection of the CNS is associated with neurological disorders ranging from mild
cognitive disorder to HIV-1-associated dementia The paradox between HIV-1-infected
target cells, i.e., microglia/macrophages and astrocytes and HIV-1-affected cells, i.e.,
neurons in the CNS has led to a number of indirect mechanisms for HIV-1
neuropathogenesis. HIV-1 Tat protein is present in the CNS, it can be directly from HIV-1-
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infected cells in the CNS, or derived from HIV-1-infected cells outside the CNS (Banks et
al. 2005; Chang et al. 1997; Chen et al. 1995). Tat can be taken up by neighboring neurons
and other brain cells (Frankel and Pabo 1988; Liu et al. 2000). Thus, Tat has been proposed
to be one of the most important viral elements responsible for HIV-1 neuropathogenesis. A
growing body of evidence has accumulated to support this hypothesis. Firstly, direct
exposure to Tat is neurotoxic, so-called acute Tat neurotoxicity, through alterations of
neuronal integrity, homeostasis and survival, neuroexcitatory property, endoplasmic
reticulum calcium load, and oxidative state (Aprea et al. 2006; Brailoiu et al. 2006;
Caporello et al. 2006; Norman et al. 2007). Secondly, Tat possesses a chemokine-like
activity; its presence results in infiltration of monocytes/macrophages and lymphocytes into
the CNS, which in turn causes neurotoxicity (Benelli et al. 2000; de Paulis et al. 2000; Jones
et al. 1998; Park et al. 2001). Thirdly, Tat alters neuronal gene expression through directly
regulating gene expression mechanisms or indirectly eliciting intracellular signaling
cascades (Liu et al. 2000; Peruzzi 2006). In addition to those direct neurotoxic effects, Tat
can also affect neuronal function and survival indirectly by interacting with other brain cells
such as astrocytes and brain endothelial cells (Andras et al. 2008; Chauhan et al. 2003; Kim
et al. 2003b; Price et al. 2006; Toborek et al. 2003; Zhong et al. 2009; Zhou and He 2004;
Zhou et al. 2004). In agreement with these findings, Tat expression in or injection into the
CNS in the absence of HIV-1 infection is sufficient to cause neuropathologies similar to
most of those noted in the brain of AIDS patients (Jones et al. 1998; Kim et al. 2003a). It is
evident from all these studies that Tat is a major contributing factor to HIV-1
neuropathogenesis.
Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein; it is
exclusively expressed in astrocytes and has been widely used as a marker for these cells [see
review (Eng et al. 2000)]. GFAP expression is developmentally and pathophysiologically
regulated. It begins to express as astrocytes mature, and its expression is always increased in
reactive astrocytes, or astrocytosis, which is one of the main characteristics of the astrocytic
reaction commonly observed in the CNS response to physical, pathological, or chemical
insults (Norenburg 1997). Interestingly, both over-expression and disrupted expression of
GFAP are problematic and result in neuropathologies. Transgenic mice with higher levels of
GFAP expression die prematurely (Messing et al. 1998), while GFAP knockout mice exhibit
some developmental defects (Gomi et al. 1995) and CNS abnormalities in the white matter,
myelination and the blood-brain barrier (Liedtke et al. 1996; Pekny et al. 1998). In addition,
GFAP mutations have been linked to a fatal disease of infants, juveniles, and adults called
Alexander's Disease (AxD) (Brenner et al. 2001). AxD is pathologically characterized by
formation of Rosenthal fibers (cytoplasmic inclusions) in astrocytes, which contain
increased amounts of GFAP in association with stress proteins similar to that of GFAP
transgenic mice (Eng et al. 1998). Thus, tightly regulated GFAP expression in astrocytes
appears to be important for maintaining astrocyte function and CNS homeostasis.
Nevertheless, the molecular mechanisms of increased GFAP expression during CNS injury
are largely unknown.
Astrocytosis, or increased GFAP expression in astrocytes is one of the very few common
and faithful hallmarks of HIV-1 infection of the CNS (Bell et al. 2006). We have shown that
Tat expression in the absence of HIV infection activates GFAP expression and alters
astrocyte function and eventually neuron survival (Kim et al. 2003a; Zhou and He 2004;
Zhou et al. 2004). We have also shown that disruption of GFAP expression significantly
relieves Tat-induced neurotoxicity (Zou et al. 2007). In this study, we aimed to further
determine the relationship between Tat and GFAP expression and its effects on HIV-1
interaction with astrocytes.
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MATERIALS AND METHODS
Cells and cell cultures
Human astrocytoma cell line U373.MG cells and human kidney epithelial cells 293T were
purchased from ATCC (Manassas, VA). Tat-expressing U373.MG cells (U373-Tat) were
described previously (Zhou and He 2004; Zhou et al. 2004). All these cells were maintained
in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine
serum (FBS), 50 units/ml penicillin and 50 μg/ml streptomycin in a 37°C, 5% CO2
incubator. Primary human fetal astrocytes were isolated from 18-19 weeks old human fetal
brain tissue (Advanced Bioscience Resources, Inc., Alameda, CA). Briefly, human fetal
brain tissue was aseptically and mechanically separated and dissociated in Ca2+/Mg2+ free
Hanks balanced salt solution (HBSS) and then treated with 0.25% trypsin at 37°C for 30
min. Trypsin digestion was stopped by washing cells with Ca2+/Mg2+ free HBSS
supplemented with 10% FBS, followed by low speed centrifugation to remove debris. Cells
were suspended and plated at an appropriate density in a high glucose DMEM containing
10% FBS, 50 units/ ml penicillin, 50 μg/ml streptomycin and 1 mM sodium pyruvate.
Culture medium was changed 24 hr following the initial plating and then every 3-4 days in
order to remove non-adherent cells. The culture was maintained in a 37°C, 5% CO2
incubator. The primary astrocytes used in the experiments were from the 3rd or 4th passage
of these cells.
Plasmids
Tat72Myc, pHIV-GFP, pHCMV-G, p300-luc and p300abcdef-luc were described elsewhere
(Li et al. 2002; Yu et al. 2004; Zhou and He 2004). pCMV-β-gal was from Clontech
(Mountain View, CA). pGfa2-luc3 reporter plasmid and p300.HA were gifts from Dr. M.
Brenner of University of Alabama at Birmingham, Birmingham, AL and Dr. C-H Chang of
Indiana University School of Medicine, Indianapolis, IN, respectively. pLTR-Luc was from
Drs. R. Jeeninga and B. Berkhout through the NIH AIDS Reagent Program.
Western blotting analysis
Cells were washed twice in ice-cold phosphate-buffered saline (PBS) and lyzed in PBS/TDS
buffer (10 mM Na2HPO4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% SDS, 0.2% sodium azide, 0.004% sodium fluoride, 1 mg/ml aprotinin, 1 mg/ml
leupeptin, 1 mM sodium orthovanadate, pH 7.25) on ice for 20 min for whole cell lysate
preparation. Protein concentration was determined using a Bio-Rad DC protein assay kit
(Bio-Rad, Hercules, CA). Whole cell lysate was electrophoretically separated by 6% sodium
dodecyl sulfate-polyacrylamide gel (SDS-PAGE) for p300 detection (100 μg protein) or by
10% SDS-PAGE for Egr-1, GFAP and β-actin detection (50 μg protein), and processed for
blotting and ECL detection with antibodies for GFAP and β-actin antibodies (Sigma, St.
Louis, MO), α-Egr-1 (Santa Cruz Biotechnologies, Santa Cruz, CA), or α-p300 (Novus
Biologicals (Littleton, CO). Blots were scanned and analyzed by the NIH Image J software,
the relative protein levels were compared to the loading control (Rel.).
RNA isolation and semi-quantitative reverse transcriptase (RT)-PCR
Total RNA was isolated using a Trizol Reagent kit (Invitrogen, Carlsbad, CA) according to
the manufacturer's instructions. RT-PCR was performed on a PE Thermocycler 9700 (PE
Applied Biosystem, Foster City, CA) using a Titan One Tube RT-PCR kit (Boehringer
Mannheim, Indianapolis, IN). The primers for p300 were 5′-ATG AAC AAC CCC AAT
CCT TAT GG-3′ and 5′-CAG GAC AAT CAT GTC TTG TAC-3′ with a program of 50°C
for 30 min, 94°C for 3 min, followed by 22 cycles of 94°C for 1 min, 50°C for 1 min and
68°C for 1 min and one cycle of 68°C for 7 min. The primers for GFAP were 5′-AAG CAG
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ATG AAG CCA CCC TG-3′ and 5′-GTC TGC ACG GGA ATG GTG AT-3′ with a
program of 50°C for 30 min, 94°C for 3 min, followed by 25 cycles of 94°C for 1 min, 52°C
for 1 min and 68°C for 1 min and one cycle of 68°C for 7 min. The primers for Tat were 5′-
GTC GGG ATC CTA ATG GAG CCA GTA GAT CCT-3′ and 5′-TGC TTT GAT AGA
GAA ACT TGA TGA GTC-3′ with a program of 50°C for 30 min, 94°C for 3 min, followed
by 30 cycles of 94°C for 1 min, 50°C for 30 sec and 72°C for 45 sec and one cycle of 72°C
for 5 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was included in the RT-
PCR as an internal control with primers 5′-CTC AGT GTA GCC CAG GAT GC-3′ and 5′-
ACC ACC ATG GAG AAG GCT GG-3′. The expected sizes for GFAP, Tat, p300, and
GAPDH amplification products were 625, 216, 494 and 500 bp, respectively. Control
reactions containing no RT were included to ensure no genomic DNA contamination in the
DNA preparations.
Preparation of VSV-G-pseudotyped HIV-GFP viruses and the RT assay
293T cells were transfected with pHIV-GFP plasmid and pHCMV-G plasmids (Li et al.
2002) using the standard calcium phosphate precipitation method. Culture supernatants were
collected 72 hr after transfection, clarified by brief low speed centrifugation to remove cell
debris, and stored in aliquots at a −80°C freezer. Mock virus with envelope was produced in
the same manner and used as a control. The virus titer was determined by the reverse
transcriptase assay.
HIV infection of U373.MG cells and primary human fetal astrocytes
U373.MG and primary human fetal astrocytes were plated at an appropriate density and
allowed to grow for 24 hr, followed by infection with VSV-G pseudotyped HIV-GFP
viruses or mock virus at the dosage of 50K cpm/per million U373.MG cells or 80K cpm/per
million primary human fetal astrocytes at 37°C for 2 hr in the presence of 8 μg/ml
polybrene. The cells were then thoroughly washed with culture medium to remove unbound
viruses and further cultured an additional 48 hr. The dosages of the viruses for infection
were titrated for U373.MG and for human primary fetal astrocytes to ensure minimal
induction of cell death and maximal infection efficiency. Bright field and GFP images were
captured using a Zeiss digital camera mounted on a Zeiss Axiovert M200 fluorescence
microscope (Carl Zeiss, Thornwood, NY).
siRNA and transfection
A smart pool of p300 siRNA and a scramble control siRNA were purchased from
Dharmacon (Lafayette, CO). U373.MG cells were plated in a 12-well plate at a density of 6
× 104/well or in a 6-well plate at a density of 2 × 105/well and were transfected with siRNA
using Lipofectamine according to the manufacturer's instructions (Invitrogen). Cells were
harvested 24 hr after transfection for RNA analysis and 72 hr after transfection for protein
analysis. For experiments involving both siRNA and plasmid transfection, U373.MG cells
were first transfected with siRNA, cultured for 24 hr, and then transfected with plasmid
DNA.
β-galactosidase and luciferase reporter gene and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) assays
Cells were harvested in ice-cold PBS and collected by brief centrifugation. After washes
with PBS, the cells were suspended in 0.25 M Tris.HCl, pH 8.3 and subject to three cycles
of freezing and thawing. The clear supernatant was saved as the cell extracts to determine
the relative β-galactosidase activity. The β-galactosidase activity was then used to normalize
the transfection variations among transfections for the subsequent luciferase reporter gene
assay, which was done using a luciferase assay system (Promega, Madison. WI). The
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luciferase activity was quantitated using an Opticomp Luminometer (MGM Instruments,
Hamden, CT). Cell viability was determined using the MTT assay as previously described
(Zhou et al. 2004).
[3H]-thymidine incorporation assay
U373.MG cells were plated in a 96-well plate at a density of 1 × 104 cells per well and
allowed to grow overnight. Then, the cells were pulse-chased with 1 μCi [3H]-thymidine
(Perkin Elmer) in each well for 48 hr. Cells were then harvested by incubating with 100 μl
0.25% Trypsin/1 mM EDTA for 20 min and transferred onto a filter paper for scintillation
counting.
Data analysis
All experiment data were analyzed by 2-tailed student's t test. A p < 0.05 was considered to
be statistically significant and marked as “*”, a p < 0.01 was considered to be statistically
highly significant and marked as “**”.
RESULTS
Identification of increased p300 cDNA level in Tat-expressing astrocytoma cells and
primary astrocytes
Our early studies have shown that Tat expression leads to increased levels of GFAP
expression in astrocytes (Kim et al. 2003a; Zhou et al. 2004). During this study, we always
noticed an additional minor RT-PCR product of about 1 kb in length that was only amplified
from Tat expressing U373-Tat cells (Fig. 1A). To ensure that this product was not an artifact
derived from RT-PCR or a selection bias from generation of U373-Tat stable cell lines, we
isolated primary embryonic astrocytes from inducible astrocyte-specific Tat transgenic mice
(Kim et al. 2003a; Zhou et al. 2004) along with primary astrocytes from wild-type C57BL/6
mice, the breeding congenic strain for Tat transgenic mice. We cultured these cells in vitro
in the presence of 5 mg/ml doxycycline to induce Tat expression, which was demonstrated
by RT-PCR using Tat specific primers (middle panel, Fig. 1B). There was a 1 kb RT-PCR
product amplified in Tat-expressing primary murine astrocytes (upper panel, Fig. 1B). We
then recovered the DNA from the agarose gel, cloned it into the TA TOPO cloning vector,
and sequenced the insert. BLAST searches matched the sequence of this DNA fragment to
p300 cDNA between nucleotide (nt.) 6475 and nt. 7436 (GenBank accession #
NM_001429). The unintended amplification of p300 was likely due to degenerative
alignment of the 5′ GFAP primer to p300 cDNA between nt. 6475 and nt. 6493 and the 3′
GFAP primer to p300 cDNA between nt. 7417 and nt. 7436.
Up-regulated p300 expression in Tat-expressing astrocytes and HIV-infected astrocytes
To determine whether Tat expression indeed led to p300 up-regulation, we prepared total
RNA from U373.MG and U373-Tat cells and performed RT-PCR using p300-specific
primers. Meanwhile, we also prepared whole cell lysates from these cells and performed
Western blot analysis using an anti-p300 antibody. Compared to U373.MG cells, U373-Tat
cells had significantly higher levels of p300 expression at both mRNA and protein levels
(Fig. 2A). To further ascertain this phenomenon, we also transiently transfected U373.MG
cells with HIV-1 Tat expression plasmid and determined p300 expression in those cells and
obtained similar results (Fig. 2B). To further determine the physiological relevance of Tat-
up-regulated p300 expression, we infected U373.MG cells with VSV-G-pseudotyped HIV-
GFP viruses, which were use to override the HIV-1 entry restriction in astrocytes and
facilitate HIV-1 infection of these cells. The infection efficiency of these viruses was
estimated to be about 40% (Fig. 3A). We then compared p300 mRNA and protein levels
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between HIV-infected and mock infected-U373.MG cells. In agreement with the findings
obtained from Tat expression, HIV-1 infection resulted in increased p300 expression at both
mRNA and protein levels (Fig. 3B). Moreover, we also infected primary human fetal
astrocytes with the HIV viruses and determined p300 expression. The infection efficiency of
these cells was about 25%, slightly lower than that of U373.MG cells (data not shown).
Nevertheless, increased p300 mRNA and protein were also noted in those cells infected with
HIV (Fig. 3C). Taken together, these results demonstrate that Tat expression alone or in the
context of HIV-1 infection leads to up-regulated p300 expression.
Transactivation of p300 promoter by HIV-1 Tat and its requirement for transcription factor
early growth response-1 (Egr-1)
Up-regulation of p300 mRNA by Tat expression raises the possibility that Tat activates p300
expression at the transcriptional level. To address this possibility, we transfected U373.MG
cells with a luciferase reporter gene under the control of p300 promoter (Yu et al. 2004)
along with increasing amounts pcTat.Myc expression plasmid and determined the direct
effect of Tat on p300 promoter activity. Tat expression activated the p300 promoter-driven
luciferase reporter gene expression in a direct and dose-dependent manner (Fig. 4A). Since
early growth resonse-1 is a major transcriptional regulator of p300 gene transcription and
expression and there are a total of four potential Egr-1 DNA binding motifs within the p300
promoter (Yu et al. 2004), we then performed co-transfections of the Egr-1 motifs-deleted
p300 promoter with HIV-1 Tat expressing plasmid to investigate a possible role of Egr-1 in
Tat-activated p300 expression. We found that deletion of Egr-1 DNA binding motifs
completely abolished the activation activity of Tat on the p300 promoter. These results
suggest that Egr-1 was required for Tat activation of p300 promoter and prompted us to
further determine the relationship between Tat expression and Egr-1 expression in
astrocytes. To this end, we performed Western blot analysis for Egr-1 expression in Tat-
expressing astrocytes using an anti-Egr-1 antibody. Compared to U373.MG cells, U373-Tat
cells had a much higher level of Egr-1 (Fig. 4B). Taken together, these findings indicate that
Tat activates p300 expression in astrocytes and involves the cis-acting elements of Egr-1
within the p300 promoter.
Regulation of constitutive and Tat-activated GFAP expression by p300
Having shown that HIV-1 Tat expression leads to GFAP activation (Kim et al. 2003a; Zhou
and He 2004; Zhou et al. 2004), we then investigated the relationship between p300 and
GFAP expression. To this end, we first determined the effect of p300 over-expression on
GFAP expression. We transfected U373.MG cells with the p300 expression plasmid and
analyzed GFAP expression by Western blotting. We found a significantly elevated level of
GFAP in p300-transfected cells (Fig. 5A). Next, we determined the effect of p300
knockdown on GFAP expression. We took advantage of the siRNA strategy and transfected
U373.MG cells with p300 siRNA. p300 siRNA was very effective in knocking down
constitutive p300 mRNA as well as p300 protein expression, while the control siRNA had
little effect (upper panels, Fig. 5B). In parallel, p300 knockdown resulted in a significantly
lower level of GFAP expression (lower panel, Fig. 5B). In addition, we performed similar
experiments in U373.Tat cells. p300 knockdown also effectively suppressed GFAP
expression in Tat-expressing astrocytes (Fig. 5C). These results indicate that p300 not only
plays an important regulatory role in constitutive GFAP expression, but also directly
participates in Tat-mediated GFAP up-regulation.
Transcriptional regulation of GFAP by p300
p300 is a multifunctional transcription co-activator with inherent histone acetyltransferase
(HAT) activity. It regulates a number of cellular genes through its direct binding to other
transcription factors or through its intrinsic HAT activity. Thus, we then investigated
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whether p300 regulation of GFAP expression also occurred at the transcription level. We
transfected U373.MG or U373-Tat cells with a luciferase reporter gene under the control of
the GFAP promoter (pGfa2-luc3) (Su et al. 2004) along with increasing amounts of the p300
expression plasmid and determined the luciferase activity. p300 expression activated the
GFAP promoter in U373.MG and U373-Tat cells (Fig. 6A). The more pronounced
activation of the GFAP promoter-driven reporter gene obtained in U373-Tat cells likely
results from p300 activation by Tat and the subsequent additive effects. To further ascertain
the role of p300 in Tat-mediated GFAP activation, we also transfected U373.MG cells with
p300 siRNA, followed by the pGfa2-luc3 plasmid and pcTat.Myc. As previously shown
(Zhou et al. 2004), Tat expression activated the GFAP promoter-driven luciferase reporter
gene expression (Fig. 6B). In agreement with previous findings (Fig. 5C), p300 knockdown
abolished Tat-mediated activation of the GFAP promoter-driven luciferase reporter gene
expression (Fig. 6B). These results offer additional evidence to support the notion that p300
is a transcription regulator of both constitutive and Tat-induced GFAP expression.
p300, HIV-1 gene expression and replication in astrocytes, and astrocyte proliferation
There are multiple blocks that contribute to the non-productive replication of HIV-1 in
astrocytes. To determine whether Tat activation of p300 could play a role in the restricted
HIV-1 restriction in these cells, we first focused on possible roles of p300 in HIV-1 gene
transcription. To test this, we transfected U373.MG cells with a luciferase reporter gene
under the control of the HIV-1 LTR promoter along with pcTat.Myc and increasing amounts
of the p300 expression plasmid and determined the luciferase activity. p300 expression
potentiated Tat transactivation activity on the HIV-1 LTR promoter (Fig. 7A). We next
determined the effect of p300 on HIV-1 replication. We transfected U373.MG cells with
increasing amounts of the p300 expression plasmid followed by infection with VSV-G-
pseudotyped HIV-GFP viruses, and then monitored HIV-1 replication. Surprisingly, p300
exhibited somewhat inhibitory effects on HIV-1 replication in these cells, although the
inhibition was not statistically significant (Fig. 7B). Meanwhile, we performed the MTT
assay to determine whether p300 expression would alter the proliferation of HIV-infected
astrocytes. We found that p300 expression increased the proliferation of HIV-infected
astrocytes in a dose-dependent manner (Fig. 7C). Similar results were obtained using the
[3H]-thymidine incorporation assay (7D).
DISCUSSION
p300 is a large nuclear molecule and evolutionarily conserved. It is a multifunctional
transcriptional co-activator with inherent histone acetyltransferase (HAT) activity, mediates
various cross-talks between different signaling pathways and participates in cellular
functions including DNA repair, cell growth, differentiation, and apoptosis (Blobel 2002).
These biological functions are primarily regulated via its HAT activity through
phosphorylation and interactions with other cellular proteins (Kalkhoven 2004). Compared
to its well-characterized biological functions, only a very few studies have reported on its
transcriptional regulation. Transcription factor early growth response 1 (Egr-1) has been
shown to regulate p300 transcription through the Egr-1 DNA-binding cis-acting elements
within the p300 promoter, intracellular signaling, or viral infection or expression of viral
protein (Cai et al. 2006; Nair et al. 2006; Saegusa et al. 2008; Yu et al. 2004). Meanwhile,
Tat is known to alter various intracellular signaling pathways (Liu et al. 2002; Peruzzi
2006). In the current study, we showed that Tat expression in or HIV-1 infection of
astrocytes led to p300 transactivation (Fig. 1-3) and that Egr-1 was directly involved in this
process (Fig. 4). Although the underlying mechanisms for Tat-induced Egr-1 or p300
expression remain to be determined, cross-talk among various intracellular signaling
pathways is likely involved. Tat-mediated p300 up-regulation appeared to be specific to
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astrocytes, as the opposite effect was noted in other cell types [our unpublished data and (de
la Fuente et al. 2002)]. Taken together, the current study provides further evidence to
support the notion that transcription is indeed a regulatory mechanism for p300 expression
and activity. In addition, these findings from the current study suggest that Tat likely exerts
its plethora of effects on the host through gene expression involving more general and
upstream transcription factors like Egr-1 and p300 (Fan et al.).
The initial observation of concurrent induction of p300 and GFAP by Tat prompted us to
further examine the relationship between p300 and GFAP expression. Our results
demonstrated that ectopic expression of p300 resulted in increased levels of GFAP
expression, whereas p300 knockdown led to decreased levels of GFAP expression (Fig. 5).
We further showed similar effects using a GFAP promoter-driven reporter gene system and
astrocytes stably expressing Tat protein (Fig. 5 and Fig. 6). These results suggest that p300
is important for both constitutive and Tat-induced GFAP expression. There are several
response elements in the upstream region of the GFAP promoter, including nuclear factor
(NF)-1, NF-κB, estrogen response element, glucocorticoid response element, activating
protein-1 binding site, and 12-O-tetradecanoylphorbol 13-acetate response element (Laping
et al. 1994). Accordingly, the main regulators of GFAP expression are hormones such as
thyroid hormone and glucocorticoids, growth factors, and inflammatory cytokines (Gomes
et al. 1999). On the other hand, p300 regulates gene expression mainly through the HAT
activity (chromatin remodeling) and/or binding to basal transcription factors and other
transcription activators or other cellular proteins (Xu et al. 1999). Thus, GFAP is probably
one of the target genes of p300 in astrocytes. Interestingly, complex formation of p300 with
STAT3 and Smads has indeed been shown to be essential for differentiation of neuronal
progenitors into astrocytes, as assessed by GFAP expression (Nakashima et al.
1999;Yanagisawa et al. 2001).
Quite a few studies have documented Tat interaction with p300 and its importance in Tat-
mediated transactivation of the HIV-1 LTR promoter. p300 acetylates Tat at Lys50 and
Lys51 and enhances Tat recycling from the TAR complex to activate transcription
elongation of the HIV-1 LTR promoter (Bres et al. 2002; Ott et al. 2004). Meanwhile, Tat
binds to and recruits p300 and other proteins to the transcription machinery within the
integrated HIV-1 LTR promoter, which subsequently leads to transactivation of the LTR
promoter (Marzio et al. 1998; Wong et al. 2005). Consistent with these findings, our results
showed that p300 potentiated Tat-mediated transactivation of the HIV-1 LTR promoter in
astrocytes (Fig. 7A). Interestingly, in the context of HIV-1 infection, p300 expression
appeared to inhibit, albeit in an insignificant manner, HIV gene expression (Fig. 7B). This
discrepancy between the LTR-driven reporter gene assay and the HIV gene expression assay
may be due to the state of the LTR, i.e., unintegrated LTR in the reporter gene assay vs.
integrated LTR in the gene expression assay, or p300 interaction with other HIV gene
products that differ between these two assay systems. Nevertheless, p300 expression
significantly promoted proliferation of HIV-infected astrocytes (Fig. 7C), suggesting that
p300 up-regulation by Tat may contribute to virus persistence and latency in the CNS
following initial HIV infection. It is clear that p300 up-regulation in astrocytes by Tat, as
shown in this study, adds another layer of complexity to the axis of Tat-p300 interaction and
its role in HIV gene expression and pathogenesis.
In summary, these results reveal a cascade of transcription networks in astrocytes that is
initiated by Tat and manifested by GFAP up-regulation and suggest two additional pathways
for astrocyte-mediated Tat neurotoxicity: one is GFAP accumulation that subsequently alters
astrocyte function, the other is enhanced survival of HIV-infected astrocytes that leads to the
establishment of an HIV-1 sanctuary in the CNS.
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Figure 1. Identification of p300 up-regulation in Tat-expressing U373 cells and primary
astrocytes
Total RNA was isolated from U373.MG and U373-Tat (A) or from primary astrocytes (B),
which were prepared from wild-type C57BL/6 mice or inducible Tat transgenic mice and
cultured in the presence of 5 mg/ml doxycycline for 3 days. The total RNA was subject to
RT-PCR using specific GFAP and Tat primers. GAPDH was included as an equal loading
control. Arrow: the unknown DNA products of about 1 kb amplified with GFAP primers
from Tat-expressing cells.
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Figure 2. p300 induction in astrocytes by HIV-1 Tat expression
A. Induction of p300 protein and mRNA in U373-Tat cells. B. Induction of p300 protein and
mRNA in U373 cells that were transiently transfected with HIV-1 Tat expressing plasmid.
U373.MG cells were plated in a 6-well plate at a density of 3 × 105/well and transfected
with pcTat.Myc or control pcDNA3 plasmid. Total RNA and whole cell lysates were then
prepared 48 hr after transfection for RT-PCR and Western blotting analysis, respectively.
GAPDH and β-actin were used as equal loading controls for RT-PCR and Western blot,
respectively.
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Figure 3. p300 induction in astrocytes by HIV-1 infection
U373.MG cells were infected with 50K cpm RTase equivalent VSV-G-pseudotyped HIV-
GFP viruses. HIV-1 infection was monitored by GFP expression and estimated to be about
40% (A). HIV-GFP viruses containing no envelope (mock) were included as a control. Total
RNA and whole cell lysates were prepared from these infected cells 48 hr after infection and
subject to RT-PCR and Western blotting analysis for p300 expression (B). C. Up-regulated
p300 expression in HIV-1-infected primary human fetal astrocytes. Primary human fetal
astrocytes were infected as stated above except for that 80K cpm RTase equivalent VSV-G-
pseudotyped HIV-GFP viruses were used and analyzed for p300 expression as above.
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Figure 4. Transactivation activity of HIV-1 Tat on the p300 promoter
A. Transactivation of the p300 promoter by HIV-1 Tat and its requirement for Egr-1.
U373.MG cells were transfected with p300 promoter-driven luciferase reporter gene (p300
promoter, closed bar) or a mutated p300 promoter-driven reporter gene that lacks all four
Egr-1 DNA binding sites (Egr-1-deleted p300 promoter, open bar) and increasing amounts
of pcTat.Myc plasmid. Cell lysates were prepared 48 hr after transfection for the Luc
activity assay. pCMV-βGal was included in transfections to normalize the transfection
variations. All samples were compared to the one that was not transfected with pcTat.Myc
for statistical analysis. B. Up-regulated expression of Egr-1 protein in U373-Tat cells. Total
RNA and whole cell lysates were prepared from U373.MG and U373-Tat cells and subject
to RT-PCR and Western blotting analysis, respectively. GAPDH and β-actin were used as
equal loading controls for RT-PCR and Western blotting analysis, respectively.
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Figure 5. Relationship between p300 and GFAP expression
A. GFAP up-regulation in astrocytes by p300 over-expression. U373.MG cells were
transfected with p300.HA expressing plasmid or control pcDNA3. Whole cell lysates were
prepared 48 hr after transfection and subject to Western blotting analysis for GFAP, p300
and β-actin expression. B & C. GFAP down-modulation in U373.MG (B) and U373-Tat
cells (C) by p300 knockdown. U373.MG and U373-Tat cells were transfected with p300
siRNA or control siRNA at the indicated concentrations. Total RNA and whole cell lysates
were prepared after transfection for RT-PCR and Western blotting analysis, respectively.
GAPDH and β-actin were used as equal loading controls for RT-PCR and Western blotting
analysis, respectively.
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Figure 6. Involvement of p300 in constitutive and Tat-mediated GFAP expression
A. Transactivation of the GFAP promoter by p300. U373.MG (open bar) and U373-Tat
(closed bar) cells were transfected with the GFAP promoter-driven luciferase reporter gene
plasmid pGfa2-luc3 and increasing amounts of p300 expressing plasmid. Cell lysates were
prepared 48 hr after transfection for the luciferase activity assay. pCMV-βGal was included
in the transfection to normalize transfection variations. All samples were compared to the
one that was not transfected with p300.HA for statistical analysis. B. Attenuation of Tat-
mediated GFAP activation by p300 knockdown. U373.MG cells were transfected with p300
siRNA or control siRNA, cultured for 24 hr, and then transfected again with pGfa2-luc3 and
pcTat.Myc. Cell lysates were prepared 48 hr after the 2nd transfection for the luciferase
activity assay. pCMV-βGal was included in transfections to normalize the transfection
variations. All samples were compared to the one that was transfected only with pcDNA3
for statistical analysis.
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Figure 7. Effects of p300 on HIV-1 gene expression and replication in astrocytes and on survival
of HIV-1-infected astrocytes
A. Activation of the HIV-1 LTR promoter by p300. U373.MG cells were transfected with
the HIV-1 LTR promoter-driven luciferase reporter gene plasmid pHIV LTR-Luc,
pcTat.Myc, and increasing amounts of p300 as indicated. Cell lysates were prepared 48 hr
after transfection for the luciferase activity assay. pCMV-βGal was included in transfections
to normalize the transfection variations. All samples were compared to the one that was
transfected only with pcDNA3 for statistical analysis. B. No significant effects of p300 on
HIV-1 replication. U373.MG cells were transfected with increasing amounts of p300
expressing plasmid as indicated, cultured for 24 hr, and then infected with VSV-G-
pseudotyped HIV-GFP viruses. Cell culture supernatants were collected 48 hr after infection
for the RT activity assay. Mock infection was included as a control. C & D. Increased
proliferation of HIV-1-infected astrocytes by p300. U373.MG cells were transfected and
infected as stated above and then subject to the MTT assay 48 hr after infection (C), or
pulse-chased with [3H]-thymidine for 48 hr for scintillation counting (D). All samples were
compared to the one that was not transfected with p300.HA but infected with HIV-1 for
statistical analysis (B-D).
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